Investment Thesis — ResMed Inc.
The market overstates long-term margin compression risk from GLP-1 obesity drugs and underappreciates ResMed's embedded pricing power and patient base stickiness. As competitors struggle with scale and regulatory hurdles, RMD's recurring revenue model and data-driven ecosystem are set to drive sustained EPS growth.
Catalysts
- Clinical data showing limited long-term efficacy of GLP-1s for sleep apnea
- Acceleration in SaaS/data revenue growth
- New reimbursement wins or device launches
Risk Factors
- Faster-than-expected GLP-1 adoption reducing device demand
- Adverse reimbursement or regulatory changes
- Execution missteps in SaaS/data integration
Key Debates
RMD's 22.75x Fwd P/E justified by 12% growth by Q4
Shorts validated as RMD's revenue growth decelerates to 7% by Q3
RMD's 22.75x P/E compresses to 19x by Q3 on reimbursement cuts